Guest guest Posted December 8, 2004 Report Share Posted December 8, 2004 HOME | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | HELP Please sign in for full text and personal services Previous Volume 348:1598-1599 April 17, 2003 Number 16 Next Natalizumab for Relapsing Multiple Sclerosis Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings. Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager E-mail When Cited E-mail When Letters Appear Related Article by , D. H. Find Similar Articles PubMed Citation To the Editor: As participants in the original exploratory study,1 we did not find that treatment with anti–4 integrin antibody was of clinical benefit. and colleagues ( Jan. 2 issue)2 report that monthly natalizumab infusions in patients with multiple sclerosis significantly reduced relapse rates and enhancing lesions on magnetic resonance imaging (MRI), but this effect was not carried forward in the six months after treatment. The treatment had no effect on the disability score (on the Kurtzke Expanded Disability Status Scale). There was no evidence that long-term natalizumab infusions modify the course of multiple sclerosis. Epidemiologic . . . [Full Text of this Article] This article has been cited by other articles: Mittelbrunn, M., Molina, A., Escribese, M. M., Yanez-Mo, M., Escudero, E., Ursa, A., Tejedor, R., Mampaso, F., -Madrid, F. (2004). VLA-4 integrin concentrates at the peripheral supramolecular activation complex of the immune synapse and drives T helper 1 responses. Proc. Natl. Acad. Sci. U. S. A. 101: 11058-11063 [Abstract] [Full Text] HOME | SEARCH | Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.